BI-1607

N/A

Report date: 2022/08/03 14:23:41

Base Information

Drug NameBI-1607
Drug Alias NameBI-1607
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionLow affinity immunoglobulin gamma Fc region receptor II-b antagonistsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants
TargetsLow affinity immunoglobulin gamma Fc region receptor II-b
Therapy Area/IndicationsUveal melanomaMetastatic breast cancerSkin Melanoma +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermanyUnited Kingdom +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBioinvent International Ab
China Registration ClassN/A

Develop Information

Active CompaniesBioinvent International Ab
Inactive CompaniesN/A
Active IndicationsUveal melanomaSkin MelanomaSolid tumours +[4] 
Inactive IndicationsMetastatic breast cancerStomach NeoplasmsEsophageal Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksN/A